Breast Cancer

Women with early breast cancer have varying outcomes with zoledronic acid treatment depending on MAF positivity, according to the AZURE trial.

Selection of more aggressive treatment options for breast cancer led to substantial employment disruptions among working patients, according to the results of a recent study.

A new randomized trial found that neoadjuvant trastuzumab/pertuzumab alone yields a substantially worse rate of pathologic complete response compared with paclitaxel plus the two anti-HER2 agents for women with early HER2-positive breast cancer.

We will provide a brief orientation on the research that has defined our understanding of breast cancer disparities to date, as well as promising emerging data sources and methods that may take us further in the quest to close the racial survival gap and provide better cancer care to vulnerable populations.

This article reviews the mechanisms of sexual dysfunction that occur after breast cancer, offers some practical guidance on how to discuss this effectively with patients, and reviews the data and recommendations for optimizing management.

Women who take multivitamin supplements before their breast cancer diagnosis and during chemotherapy appear to be less likely to develop the debilitating, often long-lasting symptoms of chemotherapy-induced peripheral neuropathy, according to a new study.

The FDA has granted Priority Review status to pertuzumab (Perjeta) for the treatment of HER2-positive early breast cancer. The FDA will review the agent in combination with trastuzumab and chemotherapy, for use in the adjuvant setting.

From 1989 to 2015, breast cancer death rates decreased by 39%, according to findings from a report from the American Cancer Society. This decrease translates to well over a quarter of a million averted breast cancer deaths in the United States.

Dr. Judy Garber offers further perspective on the topic of PARP inhibitors in triple-negative breast cancer, which she presented in an education session at 2017 ESMO.

Long-term use of the long-acting insulin analog glargine is associated with an increased risk of breast cancer in women with type 2 diabetes, according to a new population-based cohort study.

Moderate- to high-intensity exercise may lead to an acute increase in levels of epinephrine, which can reduce breast cancer cell viability and tumor growth via activation of the Hippo signaling pathway.

The FDA has approved abemaciclib for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after failure of initial therapy.

Elderly breast cancer patients with severe mental illness had a twofold increased risk of all-cause mortality compared to those without mental illness, according to a new study.

In this interview we discuss a recent study presented at ESMO on fertility-preserving procedures for women with BRCA-positive breast cancers

The relative importance of common chemotherapy side effects has shifted substantially over the last few decades, according to a new study. In general, psychosocial effects have become more important while physical effects seem less significant to patients than in the past.

Nearly one quarter of breast cancer patients with small, node-negative tumors have high-risk genomic characteristics and would likely benefit from chemotherapy, according to results of a new study presented at the 2017 ESMO Congress.

A new study found little difference with regard to efficacy or toxicity between two chemotherapy regimens used in combination with trastuzumab in older women with HER2-positive breast cancer. One of the regimens, containing docetaxel, was associated with a higher likelihood of completing trastuzumab treatment.

Annual mammography screening starting at age 40 prevents the most breast cancer deaths, according to a comparison of the three most common screening recommendations.

The AKT inhibitor ipatasertib offered improved progression-free survival over placebo when combined with paclitaxel in women with triple-negative breast cancer.

A novel ErbB inhibitor called pyrotinib was well tolerated and showed promising activity in patients with metastatic HER2-positive breast cancer, according to results of a phase I trial.

This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer.

A recent analysis of 360 primary breast cancer genomes has identified some potentially important cancer-driving mutations found within noncoding genomic regions.

At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences.

To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease.

Low levels of cytotoxic stromal tumor-infiltrating lymphocytes are predictive of benefit derived from antibody- vs small molecule–based drug approaches to HER2-positive metastatic breast cancer.